Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.41 |
| ▸ | GSK3B | P49841 | 2/20 | 0.40 |
| ▸ | GSK3A | P49840 | 1/20 | 0.40 |
| ▸ | AKT1 | P31749 | 2/20 | 0.40 |
| ▸ | LTA4H | P09960 | 3/20 | 0.39 |
| ▸ | IGF1R | P08069 | 1/20 | 0.39 |
| ▸ | AXL | P30530 | 2/20 | 0.39 |
| ▸ | CDK8 | P49336 | 2/20 | 0.39 |
| ▸ | TNIK | Q9UKE5 | 1/20 | 0.39 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.38 |
| ▸ | KDR | P35968 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | SCN4A | P35499 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | BTK | Q06187 | 2/20 | 0.36 |
| ▸ | CAMKK2 | Q96RR4 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5534996 | 0.90 | GSK3B (0.48) | GSK3BGSK3AAXLCDK8TNIK | |
| SCHEMBL5537040 | 0.89 | GSK3B (0.49) | GSK3BGSK3AAXLCDK8TNIK | |
| SCHEMBL5536712 | 0.87 | KIT (0.46) | MAP4K1AKT1 | |
| SCHEMBL5542634 | 0.87 | PRMT5 (0.45) | MAP4K1GSK3BAKT1 | |
| SCHEMBL5536743 | 0.85 | GSK3B (0.46) | GSK3BGSK3AAKT1AXLCDK8 | |
| SCHEMBL5539363 | 0.85 | CAMKK2 (0.50) | GSK3BGSK3AAKT1IGF1RAXL | |
| SCHEMBL5533779 | 0.81 | DYRK1B (0.43) | AKT1 | |
| SCHEMBL5537386 | 0.81 | AXL (0.45) | GSK3BGSK3AAXLCDK8TNIK | |
| SCHEMBL5539202 | 0.79 | KIT (0.46) | GSK3BGSK3AAKT1AXLCDK8 | |
| SCHEMBL5530500 | 0.76 | GRIN1 (0.39) | AKT1TNIKNPC1BTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7186716-B2 | 3-Pyrrol-pyridopyrazoles and 3-pyrrolyl-indazoles as novel kinase inhibitors | SUGEN, INC. (US) | 2007-03-06 | — | — | US | claimed |
| US-20040092546-A1 | 3-Pyrrol-pyridopyrazoles and 3-pyrrolyl-indazoles as novel kinase inhibitors | SUGEN, INC. | 2004-05-13 | — | — | US | claimed |
| US-7186716-B2 | 3-Pyrrol-pyridopyrazoles and 3-pyrrolyl-indazoles as novel kinase inhibitors | SUGEN, INC. (US) | 2007-03-06 | — | — | US | disclosed |
| US-7186716-B2 | 3-Pyrrol-pyridopyrazoles and 3-pyrrolyl-indazoles as novel kinase inhibitors | SUGEN, INC. (US) | 2007-03-06 | — | — | US | disclosed |
| US-7186716-B2 | 3-Pyrrol-pyridopyrazoles and 3-pyrrolyl-indazoles as novel kinase inhibitors | SUGEN, INC. (US) | 2007-03-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040092546-A1 | 3-Pyrrol-pyridopyrazoles and 3-pyrrolyl-indazoles as novel kinase inhibitors | MAP3K19, MAP3K1, MAP3K7 | MAP4K1 22/4885GSK3B 597/4885GSK3A 682/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.